Baird raised the firm’s price target on Alto Neuroscience (ANRO) to $22 from $16 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results which suggests clinical progress continues ahead of a catalyst-rich 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Promising Future for Alto Neuroscience: Buy Rating Backed by Strong Financials and Clinical Advancements
- Alto Neuroscience’s ALTO-207: A Promising Candidate for Treatment-Resistant Depression with Significant Financial Projections
- Alto Neuroscience price target raised to $25 from $15 at Jefferies
- Buy Recommendation for Alto Neuroscience Driven by Promising ALTO-207 Acquisition and Strategic Financial Backing
- Alto Neuroscience’s ALTO-101 Study: A Potential Game-Changer for Schizophrenia Treatment?